NuVasive (NUVA) Set to Announce Earnings on Tuesday

NuVasive (NASDAQ:NUVA) will be posting its quarterly earnings results after the market closes on Tuesday, October 30th. Analysts expect NuVasive to post earnings of $0.63 per share for the quarter. NuVasive has set its FY18 guidance at $2.37-2.40 EPS.

NuVasive (NASDAQ:NUVA) last announced its quarterly earnings results on Tuesday, July 31st. The medical device company reported $0.58 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.58. NuVasive had a net margin of 3.96% and a return on equity of 13.70%. The firm had revenue of $281.56 million during the quarter, compared to analysts’ expectations of $276.05 million. On average, analysts expect NuVasive to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Shares of NASDAQ NUVA opened at $62.12 on Friday. NuVasive has a 52-week low of $44.62 and a 52-week high of $72.41. The company has a market capitalization of $3.24 billion, a price-to-earnings ratio of 32.52, a price-to-earnings-growth ratio of 1.73 and a beta of 0.69.

Several research firms have recently weighed in on NUVA. BidaskClub upgraded shares of NuVasive from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 14th. Needham & Company LLC reiterated a “buy” rating and set a $80.00 price objective (up from $67.00) on shares of NuVasive in a research report on Wednesday, October 17th. BTIG Research began coverage on shares of NuVasive in a research report on Wednesday, August 1st. They set a “buy” rating for the company. Piper Jaffray Companies increased their price objective on shares of NuVasive to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 14th. Finally, Zacks Investment Research upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a research report on Tuesday, August 21st. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $68.56.

About NuVasive

NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

See Also: Stock Symbol

Earnings History for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with's FREE daily email newsletter.

Leave a Reply